tyzeka
Pharmaranks rates Tyzeka 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Tyzeka (Telbivudine) is a medication used to treat Chronic Hepatitis B.
Telbivudine · by Novartis
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Telbivudine
- Form
- Solution, Tablet
- Strength
- Telbivudine 100MG/5ML
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- chronic hepatitis b
- Manufacturer
- Novartis
- FDA application
- NDA022154
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Solution and Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Tyzeka treat?
- Tyzeka (Telbivudine) may be used to treat chronic hepatitis b, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Tyzeka rated?
- pharmaranks gives Tyzeka a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Tyzeka?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Tyzeka. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Tyzeka?
- Tyzeka is marketed by Novartis. You can see Novartis's full profile, rating, and other products on pharmaranks.
- Is Tyzeka a brand-name or generic drug?
- Tyzeka is a brand-name product with the active ingredient Telbivudine.
- Is Tyzeka available over the counter?
- No. Tyzeka is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Tyzeka come in?
- Tyzeka is currently marketed as solution and tablet, per the FDA's National Drug Code Directory.
- Is Tyzeka FDA-registered?
- Tyzeka is on record with the U.S. FDA under application number NDA022154. You can verify this on its official FDA label.
- Has Tyzeka been recalled by the FDA?
- Tyzeka has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Tyzeka safe?
- There's no single safe-or-not verdict. pharmaranks gives Tyzeka a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TELBIVUDINE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 367 reports naming TELBIVUDINE — the active ingredient in Tyzeka, and the FDA flagged 99% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- drug resistance102 reports
- blood creatine phosphokinase increased55 reports
- pathogen resistance50 reports
- myalgia42 reports
- viral mutation identified38 reports
- treatment failure34 reports
- muscular weakness30 reports
- foetal exposure during pregnancy22 reports
Read these as a signal, not a rate. A report does not mean TELBIVUDINE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Tyzeka head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
tyzeka
70/100